Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/19/2024 | Press release | Distributed by Public on 09/19/2024 14:47
Please select the service you want to use:
Smartlinks | Texas Health Resources | News | Health | Local News | Company News | Securities Issuers | Private Companies | Hospitals and Healthcare Facilities Management Companies | Corporate Debt Issuers
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact